# **1 SUPPLEMENTAL METHODS**

2

3 A graphical version of our methods can be found in **Figure S9**.

4

### 5 **BMI Stratification**

6 We stratified our cohort into three categories of BMI: High, Mid, and Low. In order to determine which 7 individuals fell into each group, we looked at the distribution of BMI for each ancestry group and sex 8 (Figures S1 and S2). Within each distribution, we decided to use the guartiles of the normal distribution 9 as our cut-offs for assigning BMI group (Figure S1). Individuals whose BMI fell above the 3<sup>rd</sup> guartile of 10 the BMI distribution were assigned to the High BMI category, those who fell below the 1<sup>st</sup> quartile were assigned to Low BMI, and those whose BMI fell between the 1<sup>st</sup> and 3<sup>rd</sup> guartile of the distribution were 11 12 assigned to the Mid BMI group. Tables S2 and S3 describe the BMI values for each ancestry and sex, as 13 well as the range of BMI values included in each group for each ancestry and sex.

14

### 15 BioMe BRSPD File QC

16 All of the BioMe-R Structured Phenotype Database (BRSPD) files underwent a fairly extensive QC 17 process to correct misspelled variable fields, remove extraneous symbols, standardize units of measure, 18 and replace spaces with underscores ("\_"). All of the files were originally delimited by the "|" symbol, and 19 thus were converted to a tab-delimited format for pheWAS use. Many files had variable fields with 20 variations on the same phenotype or measure (for example 1mg/mL could be written as "1 mg/mL". 21 "1mg/mL", "1mg1mL", "1mg/1mL", etc.). These measures and phenotypes needed to be collapsed and 22 standardized before input into pheWAS. Likewise, there were a few phenotypes, specifically the vital sign 23 measurements, where each individual had many measurements, with each measurement representing an 24 encounter with the healthcare system. In order to look at the overall association with these phenotypes, 25 continuous vital sign measures with multiple entries were collapsed into four measures: highest measure 26 recorded, lowest measure recorded, mean measure, and variance of measure.

27

28 Allergies

Known allergies and notes on allergic reaction were entered in the original Allergy file, which included individual ID, allergen, date of entry, and notes on the allergic reaction (if available). Most QC of the allergy file entailed collapsing variables of the same or similar phenotype. For example, allergy to tree nuts could be noted as "TREE NUT", "TREE NUTS", "TREE NUT UNSPECIFIED", and "NUT, TREE". All of these phenotypes were collapsed into the category of "TREE NUT". After QC of the Allergy file and application of selection criteria for sample size and phenotype counts, we had a total of 113 Allergy phenotypes available for pheWAS. These phenotypes are listed in **Table S12**.

36

#### 37 Encounter Diagnosis

38 The encounter diagnosis file comprises the primary diagnoses, denoted by the International Classification 39 of Disease (ICD) 9 and 10 codes, assigned to each patient by the clinician in their visits and interactions 40 with the health system. Most diagnosis codes in the encounter diagnosis file are ICD-10 codes, however, 41 there were a few diagnoses that were still using ICD-9 codes that had not been converted. We converted 42 the original encounter diagnosis file, which consisted of information on patient ID, diagnosis code, date of 43 entry, notes, and code description, into counts of each diagnosis code per individual. The PheWAS R 44 package createPhewasTable function uses this count information to select cases of a particular diagnosis 45 to have a count of 2 or more diagnosis codes, select controls with counts of 0 and exclude individuals 46 with only 1 count of a particular code. After QC, we had a total of 2,178 phenotypes available for pheWAS 47 (Table S7).

48

#### 49 Encounter Orders

The encounter orders file describes the various lab tests and other procedures ordered by the clinician upon the individual's encounter with the healthcare system. Similar to the encounter diagnosis file, the encounter orders file includes individual ID, the encounter order procedure code, date of encounter, any notes from the clinician, and notes on whether the order was complete or currently being carried out. For this phenotype, each individual was noted as "TRUE" or "FALSE" as to whether they were assigned a particular order. After QC, there were a total of 1,609 phenotypes available for pheWAS (**Table S13**). Descriptions of the procedure codes were available in the original encounter orders file. 57

#### 58 Family History

59 Family history of disease phenotypes were noted with the relation with the disorders such as mother, 60 father, sister, brother, paternal grandmother, maternal grandmother, etc. We collapsed each phenotype 61 based on the relationship degree in order to reduce the number of tests. Relationships of mother, father, 62 sister, brother, son, daughter, and child were categorized as "first degree". Grandchild, half-brother, half-63 sister, maternal aunt, maternal grandfather, maternal grandmother, maternal uncle, paternal aunt, 64 paternal grandfather, paternal grandmother, and paternal uncle were categorized as "second degree". 65 Cousin, maternal great aunt, maternal great grandfather, maternal great grandmother, maternal great 66 uncle, paternal great aunt, paternal great grandfather, paternal great grandmother, and paternal great 67 uncle were categorized as "third degree". Foster, spouse, stepbrother, stepfather and stepsister were 68 categorized as "no relation". After QC, there were a total of 144 phenotypes for pheWAS. All available 69 phenotypes are listed in Table S14.

70

#### 71 Medications

72 We used CLAMP, a clinical natural language processing algorithm, to identify the core ingredients of 73 unique Bio*Me*<sup>™</sup> prescriptions from the EHR-derived medications file. Using the unstructured Bio*Me*<sup>™</sup> 74 prescriptions as input, CLAMP returns an RxNorm concept unique identifier (RXCUI) for any prescription 75 that contains a suspected drug name. After manual review of 100 random RXCUIs output by CLAMP, 76 each RXCUI from CLAMP was then reintroduced to the RxNorm API to standardize the drugs by their 77 ingredients. From this we were able to collapse and standardize medication names for PheWAS based 78 on their common drug name. For example, sertraline, the generic name for the brand-name SSRI Zoloft, 79 would encompass prescriptions for both the generic name "sertraline" as well as "Zoloft". After QC a total 80 of 951 medication phenotypes were available for pheWAS (Table S11).

81

82 Personal History

Personal history phenotypes were extracted from a large 156-question questionnaire that had information
on demographics, social history, education, behavior, personal medical history, and more. After QC, a
total of 35 phenotypes were available for pheWAS. Table S15 lists all phenotypes available for analysis.

86

## 87 Social History (Alcohol, Illicit Drug and Tobacco use; Sexual History)

88 Social history variables containing information on education, tobacco and alcohol use, illicit drug use, and 89 sexual history were available within the BRSPD files. We split this file into multiple phenotype files 90 encompassing categorical and continuous measures of tobacco, alcohol and illicit drug use, as well as 91 sexual history. Continuous measures of alcohol use were measured as ounces of alcohol consumed per 92 week, illicit drug use was measured as frequency or number of times used, and tobacco use was 93 separated into two continuous measures of number of cigarette packs smoked per day and number of 94 years of tobacco use. Categorical measures of alcohol, illicit drug and tobacco use included Y/N 95 questions on use and exposure (yes/no) and type of user (current, past, never), as well as type of 96 tobacco (cigarettes, cigars, pipes or chew). Sexual history consisted of categorical measures of sexual 97 activity and contraceptive use. Phenotypes available for social history are described in Table S9. 98 Distributions of continuous phenotypes are shown in **Figure S10**.

99

100 OBGYN History

101 Obstetric history was derived from a file that included individual, type of pregnancy and/or parity (term,

102 preterm, ectopic, abortion, therapeutic abortion, spontaneous abortion, para, and gravida), and date of

103 OBGYN encounter. We took the OBGYN file and created two phenotype types for our pheWAS: (1)

104 categorical Y/N for presence of a certain OBGYN outcome (2) continuous counts of the OBGYN outcome

- 105 (Figure S11). Table S16 describes OBGYN phenotypes available.
- 106

107 Vital Signs (Height, Weight, Blood Pressure, Temperature, Respirations, Pulse, Pulse Oximetry, Pain

108 Score, and Pain Location)

109 The original vital signs file included information on Individual ID, type of vital sign, vital sign measure, unit

110 of measure, and date of measurement for nine signs: blood pressure, height, pain score and location,

111 pulse, pulse oximetry, respirations, temperature, and weight. Multiple measures were made for each

112 individual's encounter with the Mount Sinai health system. To account for these multiple measures we 113 first removed any measurements that were clear, biologically impossible outliers (e.g. an individual who 114 had a height measurement of 1,200 inches), then standardized all measurements to the same unit (e.g. 115 cm for height, kg for weight and degrees Celsius for temperature), and finally summarized each 116 individual's measurements into four measures per phenotype: highest recorded measurement, lowest 117 recorded measurement, mean measurement and variance. Blood pressure measurements were given as 118 separate systolic and diastolic pressure measurements, and we also included a measure of pulse 119 pressure, which was calculated as the difference between systolic and diastolic measurements. Table S6 120 and **Figure S12** describe vital sign phenotypes available and their distributions.

121

For the weight phenotype, we chose to use three measurements: highest recorded weight, lowest recorded weight, and weight change over time, which was calculated by using the earliest and most recent recorded weight measures divided by the number of years between those records as the average number of kg change per year. This obviously will not reflect weight cycling and other trajectories over time, but gives us a rough mean estimate of weight fluctuation over time. Future analyses will include more precise weight trajectories for our pheWAS. Distribution of weight phenotypes is shown in **Figure S13**.

129

130 For pain score and location, we created measurements that we hoped captured both the severity of pain 131 recorded (pain score is a 0 to 10 scale, with 0 as no pain and 10 being the most severe pain ever 132 experienced), as well as the number of times an individual reported a particular pain score. We created 133 pain score measurements that included highest recorded (with a maximum value of 10), mean pain score, 134 and pain score sum, which was the sum of all recorded pain score measurements. In addition to pain 135 score, we also had pain location recorded with pain score. We further created pain score by location. 136 where each location was assessed for highest, mean, and sum pain scores. We looked at pain location 137 overall, regardless of score, as an additional phenotype. Table S10 and Figure S14 describe pain score 138 phenotypes available and their distributions.

# 141 SUPPLEMENTAL RESULTS

#### 142 S-PrediXcan of AN

- 143 We used a binomial test to look for tissue enrichment within our experiment-wide significant gene-tissue 144 associations and found no significant enrichment of any tissue. We then looked at tissue enrichment 145 across nominally significant gene-tissue associations (p<0.05) and found significant enrichment of whole 146 blood tissue (p=5.77 x 10<sup>-7</sup>, proportion of tests=0.0232, proportion of hits=0.0290), as well as significant under-enrichment in CMC DLPFC ( $p < 2.20 \times 10^{-16}$ , proportion of tests=0.0398, proportion of hits=0.0171) 147 148 and GTEx Testis tissues (p=0.02994, proportion of tests=0.0335, proportion of hits=0.0306). 149 150 AN-GReX PheWAS 151 Full summary statistics from our AN-GReX PheWAS for all phenotypes can be found in Table S17. 152 153 Allergies 154 After QC, a total of 179 allergy phenotypes were tested for association with AN-GReX. In the overall 155 Bio*Me*<sup>™</sup> cohort, downregulation of *PFKFB4* was associated with allergy to both the antibiotic tetracycline 156 (Skin Not Sun Exposed-*PFKFB4*, p=4.12 x 10<sup>-6</sup>) and gut motility drug metoclopramide (Brain cortex-157 PFKFB4, p=9.49 x 10<sup>-6</sup>). Similarly, in individuals with Mid and Low BMI, downregulation of PFKFB4 was 158 associated with allergy to tetracycline (Mid-Skin Not Sun Exposed-*PFKFB4*, p=1.13 x 10<sup>-5</sup>; Mid-Skin Sun 159 Exposed-PFKFB4, p=2.90 x 10<sup>-4</sup>: Low-Skin Not Sun Exposed-PFKFB4, p=4.51 x 10<sup>-4</sup>). Downregulation of 160 PFKFB4 in individuals with Mid BMI was also associated with allergy to the diabetic drug metformin (Mid-161 Lung-*PFKFB4*,  $p=1.44 \times 10^{-4}$ ) and upregulation to the analgesic acetaminophen (Mid-Esophagus 162 Mucose-PFKFB4, p=9.28 x 10<sup>-6</sup>). Additionally, downregulation of PFKFB4 was associated with allergy to 163 the antibiotic vancomvcin in High BMI individuals (High-Brain Cortex-*PFKFB4*, p=9.89 x 10<sup>-5</sup>: High-Cells 164 Transformed lymphocytes-*PFKFB4*,  $p=3.37 \times 10^{-4}$ ). Upregulation of *SLC2A10* was associated with allergy to morphine in the overall cohort (Colon transverse-SLC2A10, p=1.85 x 10<sup>-5</sup>; Esophagus Mucosa-165 166 SLC2A10, p= $8.10 \times 10^{-5}$ ). Additional allergy associations are provided in **Table S12**.
- 167

#### 168 Encounter Orders

Encounter orders are coded orders from the EHR for various laboratory tests and procedures, dietary restrictions and other medication orders. After QC, there were a total of 2,147 unique encounter order codes tested for association with AN-GReX. Full summary statistics for encounter orders are provided in **Table S13**.

- 173
- 174 In the overall cohort, downregulation of ARIH2, NCKIPSD and DALRD3, and upregulation of CCDC71,
- 175 SPINK8 and WDR6 were associated with encounter order "DIET24", an order for a regular diet (Heart Left
- 176 Ventricle-ARIH2, p=8.95 x 10<sup>-6</sup>; Multiple tissues-*NCKPISD*, p<2.21 x 10<sup>-5</sup>; Cells Transformed
- 177 Lymphocytes-*DALRD3*, p=8.33 x 10<sup>-6</sup>; Brain Frontal Cortex-*CCDC71*, p=1.75 x 10<sup>-5</sup>; Brain Hippocampus-
- 178 SPINK8, p=1.21 x  $10^{-5}$ ; Brain Frontal Cortex-*WDR*6, p=1.02 x  $10^{-5}$ ; Brain Putamen basal ganglia-*WDR*6,
- 179 p=7.59 x  $10^{-6}$ ; Brain Substantia Nigra-WDR6, p=3.79 x  $10^{-6}$ ). ARIH2, CCDC71 and WDR6 were
- additionally associated with encounter order "OPH1122", coded for "Ophthalmoscopy subsequent
- 181 performed", along with upregulation of *CCDC36* (Upregulation-Heart Left Ventricle-ARIH2, p=2.17 x 10<sup>-5</sup>;
- 182 Upregulation-Multiple tissues-CCDC36, p<1.95 x 10<sup>-5</sup>; Downregulation-Multiple tissues-CCDC71, p<2.09
- 183 x  $10^{-5}$ ; Downregulation-Brain Putamen basal ganglia-WDR6, p=1.84 x  $10^{-5}$ ). Additional encounter orders
- associated with AN-GReX in the overall cohort include order "51701" for insertion of a bladder catheter,
- 185 "97112" for Neuromuscular re-education, "96372" for therapeutic, prophylactic and diagnostic injections
- and infusions, "100696" for a pregnancy-induced hypertension panel, "102915" for IFE interpretation,
- 187 "600536" for pelvic ultrasound and "NUR577" for calorie count (**Table S13**).
- 188

Downregulation of *ARIH2*, *CCDC36*, and *DALRD3* and upregulation of *CCDC71* and *WDR6* (all of which were all associated with "DIET24" in the overall cohort), were associated with encounter order "PRE5" for fall precautions in individuals with Low BMI (p< $3.85 \times 10^{-5}$ ; **Table S13**). Additional associations within individuals of Low BMI were downregulation of *SLC26A10* with order "100478" for surveillance of multidrug-resistant gram-negative bacterial respiratory infection (Low-Liver-*SLC26A10*, p= $1.70 \times 10^{-5}$ ), downregulation of *FBLIM1* with code "600536" for non-obstetric pelvic ultrasound (Low-DLPFC-*FBLIM1*, p= $3.49 \times 10^{-5}$ ), and downregulation of *DALRD3* with "DIET13" for a clear liquid diet (Low-Liver-*DALRD3*,

p=2.98 x 10<sup>-5</sup>). In individuals with High BMI, upregulation of ARIH2 was associated with code "82565" for 196 197 a creatinine serum lab order (High-Brain Amvadala-ARIH2,  $p=2.87 \times 10^{-5}$ ) and downregulation of WDR6 198 and TMEM89 was associated with code "51701" for bladder catheter insertion (High-Artery Aorta-199 TMEM89,  $p=1.77 \times 10^{-5}$ ; High-Thyroid-WDR6,  $p=2.35 \times 10^{-5}$ ). Additional encounter order codes 200 associated with AN-GReX in individuals with High BMI were "DIET50" for a renal diet, "CON65" for a 201 consult to social worker, "PR157" for post-diagnostic catheter nursing intervention, "PRL166" for physician 202 notification, "101186" for an abdominal pain panel, "NUR17" for pain assessment, "82040" for albumin 203 blood measurement, and "NUR463" for obtaining height and weight measures (Table S13).

204

## 205 Family History

206 After QC a total of 144 phenotypes were available from family history data derived from the EHR (Table 207 **S14**). Family history phenotypes were initially collapsed based on degree of relatedness into "first 208 degree", "second degree" and "third degree" categories (see Supplementary Methods). Upregulation of 209 MGMT was associated with a first-degree family history of HIV infection in both the overall cohort (p<3.33 210 x  $10^{-4}$ ) and in individuals with low BMI (p<7.93 x  $10^{-4}$ ) across multiple tissues. This association passed the 211 phenotype-wide threshold of  $p=1.64 \times 10^{-5}$  in individuals with low BMI (Low-Brain Hippocampus-*MGMT*, 212 p=6.93 x 10<sup>-7</sup>; Low-Subcutaneous Adipose-*MGMT*, p=7.53 x 10<sup>-6</sup>; Low-Brain Caudate basal ganglia-*MGMT*, p=1.09 x 10<sup>-5</sup>; Low-Brain Amygdala-*MGMT*, p=1.14 x 10<sup>-5</sup>; Low-Colon Sigmoid-*MGMT*, p=1.46 x 213 214 10<sup>-5</sup>).

215

# 216 *Medications*

After QC, a total of 1,086 unique medications/drug components were tested for association with AN-GReX. All associations with medications are shown in **Table S11**. In the overall cohort, upregulation of MHC-gene *CLIC1* was associated with multiple insulin- and diabetes-related medications including glucagon (Spleen-*CLIC1*, p=4.20 x  $10^{-9}$ ), insulin aspart, insulin detemir, insulin degludec, insulin glulisine, insulin glargine, insulin lispro, insulin isophane, regular insulin and liraglutide (Subcutaneous Adipose-*CLIC1*, p<3.27 x  $10^{-5}$ ). Upregulation of *KREMEN1* and *RBM6*, and downregulation of *PFKFB4* were also associated with insulin- and diabetes-related phenotypes (Insulin aspart-Liver-*KREMEN1*, p=2.81 x  $10^{-5}$ ; 224 insulin glargine-Liver-KREMEN1, p=4.16 x 10<sup>-5</sup>; insulin isophane-Liver-KREMEN1, p=4.31 x 10<sup>-5</sup>; 225 linaoliptin-Skin Not Sun Exposed-*PFKFB4*, p=3.91 x 10<sup>-5</sup>; insulin isophane-Brain Substantia Nigra-*RBM6*. p=3.96 x 10<sup>-5</sup>). In the overall cohort, downregulation of *RNF123* was associated with the benzodiazepine 226 sedative temazepam (Artery Aorta-RNF123, p=2.76 x 10<sup>-6</sup>), stimulant laxative sennosides (Esophagus 227 228 Mucosa-RNF123, p=1.33 x  $10^{-5}$ ; Skeletal Muscle-RNF123, p=6.88 x  $10^{-6}$ ), and diuretic 229 hydrochlorothiazide (Esophagus Muscularis-*RNF123*, p=3.73 x 10<sup>-5</sup>). Upregulation of *KREMEN1* was also 230 associated with the hydrochlorothiazide (Adipose Visceral Omentum-KREMEN1, p=4.55 x 10<sup>-5</sup>). 231 Downregulation of *PFKFB4* was associated with type 2 diabetes medication empagliflozin (Skin Not Sun 232 Exposed-*PFKFB4*, p=1.58 x 10<sup>-5</sup>) and anti-diarrheal loperamide (Skin Not Sun Exposed-*PFKFB4*, p=2.19 233 x 10<sup>-5</sup>). Additional overall AN-GReX associations with medications include antibiotic bacitracin (DLPFC-C3orf62, p=4.28 x 10<sup>-5</sup>), SSRI antidepressant sertraline (Brain Cerebellum-MGMT, p=2.53 x 10<sup>-5</sup>), 234 235 analgesic salicylic acid (Brain Caudate basal ganglia-*NICN1*, p=1.90 x 10<sup>-5</sup>), HIV antiviral lopinavir (Brain 236 Hippocampus-SLC26A6, p=1.72 x 10<sup>-6</sup>) and immunosuppressant chloroquine (Cells Transformed 237 lymphocytes-*SLC2A10*, p= $3.71 \times 10^{-5}$ ).

238

239 Within the BMI-stratified groups, we find that CLIC1 upregulation is similarly associated with glucagon in 240 individuals in the Mid BMI group (Mid-Spleen-CLIC1, p=2.09 x 10<sup>-6</sup>), and the association of CLIC1 GReX 241 with glucagon remains fairly similar across BMI groups (Figure S8). Chemotherapy drug Paclitaxel is 242 associated with upregulation of SUOX (Mid-DGN Whole Blood-SUOX,  $p=1.15 \times 10^{-6}$ ) and upregulation of 243 PFKFB4 with anti-muscarinic drug mirabegron in Mid BMI individuals (Mid-Esophagus Mucosa-PFKFB4, p=1.77 x 10<sup>-6</sup>). In individuals of High BMI, downregulation of MST1 was associated with anti-diarrheal 244 245 hormone octreotide (High-Adrenal gland-MST1, p=4.71 x 10<sup>-6</sup>) and downregulation of *PFKFB4* was 246 associated with antidiabetic repaglinide and anti-tremor and gut antispasmodic Hyoscyamine (Repaglinide-High-Skin Sun Exposed-*PFKFB4*, p=7.92 x 10<sup>-6</sup>; Hvoscvamine-High-Skin Not Sun Exposed-247 PFKFB4, p=1.39 x 10<sup>-5</sup>). Among Low BMI individuals, top associations include upregulation of GPX1 with 248 prescription for lanolin oil (Low-Adipose Visceral Omentum-GPX1, p=8.25 x 10<sup>-6</sup>; Low-Ovary-GPX1. 249 p=3.33 x 10<sup>-6</sup>). Additionally, downregulation of USP19 was associated with osteoporosis drug Teriparatide 250

in individuals with Low BMI (Low-Pituitary-*USP19*, p=7.84 x  $10^{-6}$ ). Additional associations of AN-GReX with medications are found in **Table S11**.

253

# 254 **OBGYN History**

255 OBGYN phenotypes were extracted from the EHR and contained the following categories along with date 256 of outcome: abortion, current pregnancy, ectopic pregnancy, para (parity), gravida, preterm birth, 257 spontaneous abortion, to-term birth and therapeutic abortion. PheWAS were run on two (iterations) of the 258 data: (1) Overall having any phenotype as a categorical TRUE/FALSE and (2) continuous counts of each 259 phenotype (Sample numbers are available in **Table S18**). Upregulation of *KREMEN1* in individuals with 260 high BMI was associated with overall parity, or the number of births per gestation (Subcutaneous 261 adipose-KREMEN1,  $p=1.16 \times 10^{-4}$ ). Downregulation of SLC26A10 was also associated with parity, but in 262 individuals of low BMI (Subcutaneous adipose-SLC26A10, p=2.03 x 10<sup>-5</sup>). All associations are shown in 263 Table S16. For continuous measures of OBGYN outcomes, CLIC1 upregulation was associated with 264 greater counts of preterm pregnancies in the overall cohort (Adipose Subcutaneous-CLIC1, p=4.05 x 10<sup>-6</sup>) and in High BMI individuals (High-Adipose Subcutaneous-CL/C1, p=1.55 x 10<sup>-8</sup>). Downregulation of 265 266 LAMB2 was also associated with number of preterm pregnancies in High BMI individuals (High-Adipose Subcutaneous-LAMB2, p=2.68 x 10<sup>-6</sup>). Additional associations of AN-GReX with continuous OBGYN 267 268 outcomes are described in Table S16.

269

#### 270 Personal History

271 We tested a total of 35 phenotypes listed as "Personal History of Disease" in BioMe<sup>™</sup> (Table S16). 272 Upregulation of ARIH2, C3orf62, CCDC36, CELSR3, DALRD3, NCKIPSD, NDUFAF3, NICN1 and 273 P4HTM, and downregulation of CCDC71, GPX1 and WDR6, were associated with personal history of 274 Lupus in the overall cohort, as well as in individuals with Mid BMI, in multiple tissues (Overall, p<1.42 x 275  $10^{-3}$ ; Mid, p<1.41 x  $10^{-3}$ )(Figure S15). All of these genes fall within the chromosome 3 locus from our S-276 PrediXcan results (Figure 1, Table S4). Additionally, MHC-gene CLIC1 was also associated with a personal history of Lupus in the overall cohort (Skeletal Muscle-CLIC1, p=7.57 x 10<sup>-4</sup>; Spleen-CLIC1, 277 p=6.72 x 10<sup>-4</sup>; Subcutaneous Adipose-*CLIC1*, p=2.01 x 10<sup>-4</sup>). In individuals with Mid BMI, upregulation of 278

279 ARIH2, C3orf62, CCDC36, CELSR3, DALRD3, NCKIPSD, NICN1, P4HTM and USP19, and

downregulation of CCDC71, GPX1, LAMB2, and WDR6, was associated with a personal history of high

blood pressure (p<1.42 x  $10^{-3}$ ). Similarly, upregulation of ARIH2, CCDC36, CELSR3, DALRD3,

282 NCKIPSD, NDUFAF3, P4HTM and downregulation of WDR6 was associated with a personal history of

kidney disease in individuals with Mid BMI ( $p<1.39 \times 10^{-3}$ ). Additional associations are shown in **Table** 

284 **S15**.

285

## 286 Social History (additional results)

287 Sample numbers for social history phenotypes can be found in Tables S19 through S22. Phenotypes of 288 sexual history, such as sexual activity, contraceptive use and type, as well as information about sexual 289 partner, were derived from the social history questionnaire. A total of eight phenotypes were tested for 290 association with AN-GReX\*: (1) Sexually active (Y/N) (2) Self-reported female or male partner (3) 291 Contraceptive method: abstinence, condom, injection, IUD, and pill (\*phenotypes are categorized as Y/N 292 or T/F). In the overall cohort, upregulation of RBM6 and SEMA3F and downregulation of MST1R and 293 *RNF123* were associated with being sexually active across multiple tissues (*RBM6*,  $p < 5.46 \times 10^3$ ; SEMA3F, p<4.51 x  $10^{-3}$ ; MST1R, p<4.60 x  $10^{-3}$ ; RNF123, p<4.50 x  $10^{-3}$ ). Within our stratified BMI 294 295 analyses, downregulation of APEH was associated with being sexually active in individuals of High BMI 296 (High-Esophagus Muscularis-*APEH*, p=4.63 x 10<sup>-5</sup>). Additionally in individuals of High BMI, upregulation 297 of GPX1 was associated with IUD use (High-Esophagus Mucosa-GPX1, p=8.11 x 10<sup>-5</sup>). All associations 298 are described in Table S9.

299

# 300 Anthropometric traits and Vital signs

301 Vital signs were measured for individuals at most if not all encounters with the healthcare system.

302 Measurements of blood pressure, height, pain score and location, pulse, pulse oximetry, respirations,

303 temperature and weight were recorded for each individual for each encounter. Vital sign measurements

304 were standardized and QC of these measurements is described in the **Supplementary Methods**. Full

305 results for vital signs are shown in **Table S6**.

307 Blood Pressure

308 Blood pressure measures were split into three factors: diastolic pressure, systolic pressure, and pulse 309 pressure (see Supplementary Methods), with highest ever measure, lowest ever measure, mean 310 measure and variance calculated for each phenotype. In the overall cohort, upregulation of RBM6 and 311 downregulation of MST1R and RNF123 were associated with diastolic and systolic highest measurements in multiple tissues (Diastolic highest-*RBM6*,  $p < 9.70 \times 10^{-4}$ ; Diastolic highest-*MST1R*, 312 313  $p < 9.27 \times 10^{-4}$ ; Diastolic highest-*RNF123*,  $p < 8.56 \times 10^{-4}$ ; Systolic highest-*RBM6*,  $p < 9.74 \times 10^{-4}$ ; Systolic highest-MST1R, p<7.08 x 10<sup>-4</sup>; Systolic highest-RNF123, p<8.89 x 10<sup>-4</sup>). Upregulation of NCKIPSD, 314 315 NDUFAF3, and P4HTM, and downregulation of WDR6 were associated with lowest systolic pressure in the overall cohort (multiple tissues,  $p < 9.68 \times 10^{-4}$ ). BMI-stratified associations are described in the full 316 317 summary statistics in Table S6. 318 319 Height 320 Height for individuals in BioMe<sup>™</sup> was standardized to centimeters units of measure (see Supplementary 321 **Methods**). In the overall cohort, there were four genes associated with measures of mean height. Upregulation of CLIC1, GPR75 and LINC00324 and downregulation of CTNNB1 were associated with <sup>4</sup>; Artery Tibial-*GPR75*, p=5.07 x 10<sup>-4</sup>; Skin Sun Exposed-*LINC00324*, p=6.51 x 10<sup>-4</sup>; Brain Amygdala-324 CTNNB1, p=2.28 x 10<sup>-4</sup>; Brain Caudate basal ganglia-CTNNB1, p=1.67 x 10<sup>-4</sup>; Brain Putamen basal 326 ganglia-CTNNB1, p=4.65 x 10<sup>-4</sup>). GPR75 and CLIC1 upregulation were also associated with mean height among the Mid BMI individuals (Mid-Adipose Subcutaneous-CLIC1, p=4.31 x 10<sup>-4</sup>; Mid-Arterv Tibial-327 *GPR75*.  $p=1.44 \times 10^{-4}$ ). Full summary statistics are available in **Table S6**. 328 330 Pain Score and Location (Additional results) 331 Pain score and location measurements were described within the vital sign files from the BioMe<sup>™</sup> 332 BRSPD files. QC of pain score and pain location phenotypes are available in the **Supplementary** 333 Methods. Final phenotypes available for pain score include highest ever, sum pain score and mean pain

334 score. Pain location resulted in a total of 25 location phenotypes: abdomen, ankle, back, breast, chest,

322

323 mean height (Adipose Subcutaneous-*CLIC1*, p=1.39 x 10<sup>-5</sup>; Adipose Subcutaneous-*GPR75*, p=3.51 x 10<sup>-5</sup>

325

costal left, costal right, elbows, feet, generalized, groin, hands, head, knees, left leg, lower extremities,
neck, pelvis, perineum, right leg, sacrum, shoulder, throat, upper extremities and wrist. Pain score by
location phenotypes included measures of highest ever, sum and mean pain scores for each location
type.

339

340 Upregulation of *SLC2A10* was associated with mean pain score in the overall cohort (Adrenal Gland-

341 *SLC2A10*, p=9.94 x 10<sup>-4</sup>). Upregulation of *SLC2A10* was also associated with mean pain score in Low

342 BMI individuals (Low-Adrenal Gland-*SLC2A10*, p=6.54 x 10<sup>-5</sup>). In High BMI individuals, downregulation of

343 *MGMT* was associated with mean pain score in multiple tissues (High-*MGMT*,  $p < 9.48 \times 10^{-4}$ ).

Downregulation of *PROS1* was also associated with mean pain score in the High BMI group (High-Artery Aorta-*PROS1*, p=8.06 x  $10^{-4}$ ). Downregulation of *CLIC1* and downregulation of *MGMT* were associated with pain score sum in Low and High BMI groups respectively (Low- Testis-*CLIC1*, p=2.83 x  $10^{-4}$ ; High-

347 Spleen-*MGMT*,  $p=1.85 \times 10^{-5}$ ).

348

349 For measures of pain location only, many genes were associated with pain location in the overall cohort, 350 as well as among the stratified BMI groups. In the overall cohort, upregulation of ARIH2, C3orf62, 351 DALRD3, NCKIPSD and downregulation of GPX1 and WDR6 were associated with throat pain. CTNNB1 352 was associated with back (upregulation), chest (upregulation) and left leg pain (downregulation). 353 Upregulation of MST1R and RNF123 was associated with breast pain in the overall cohort, and 354 upregulation of CHAC2 and P4HTM, and downregulation of LINC00324 were associated with costal left 355 pain. All summary statistics for AN-GReX associations with pain location are located in Table S10. Within 356 our stratified BMI groups, we see large numbers of associations of generalized pain location and foot pain 357 with Low BMI individuals. There are a total of 55 gene-tissue associations of AN-GReX with generalized pain, and 129 associations with foot pain (Generalized p<1.88 x  $10^{-3}$ . Foot p <2.03 x  $10^{-3}$ ). Some of the 358 359 genes included in those associations include RBM6 upregulation with generalized pain (32 associations, 360 p<1.16 x 10<sup>-3</sup>), MST1R downregulation with generalized pain (13 associations, p<1.07 x 10<sup>-3</sup>), CCDC36 361 downregulation with foot pain (19 associations,  $p < 1.76 \times 10^{-3}$ ), *NCKIPSD* downregulation with foot pain

362 (33 associations, p<1.90 x  $10^{-3}$ ), and upregulation of *WDR6* with foot pain (32 associations, p<2.03 x  $10^{-3}$ ). Full summary statistics for each body location are available in **Table S10**.

364

365 When merging pain score with pain location, multiple AN genes were associated with measure of pain in 366 various bodily locations (Table S10). In the overall cohort, upregulation of CTNNB1, TMEM89 and 367 TNFSF12 was associated with throat pain score sum (Nerve Tibial-CTNNB1, p=4.92 x 10<sup>-10</sup>; Artery Aorta-*TMEM89*,  $p=1.25 \times 10^{-5}$ ; Brain Cerebellar Hemisphere-*TMEM89*,  $p=2.39 \times 10^{-6}$ ; Nerve Tibial-*TNFSF12*, 368 369  $p=8.20 \times 10^{-7}$ ). Upregulation of *KREMEN1* was associated with highest ever elbow pain as well as mean 370 elbow pain measures (Highest-Artery Aorta-*KREMEN1*, p=3.62 x 10<sup>-6</sup>; Mean-Artery Aorta-*KREMEN1*. 371 p=1.43 x 10<sup>-6</sup>). Downregulation of ASB3 and SEMA3F, and upregulation of LAMB2 were associated with knee pain score sum (Cells EBV-transformed-ASB3, p=3.81 x 10<sup>-5</sup>; Brain Substantia nigra-SEMA3F, 372 373  $p=2.03 \times 10^{-6}$ ; DGN Whole Blood-*LAMB2*,  $p=3.86 \times 10^{-5}$ ). Upregulation of *EBF3* was associated with hand 374 pain score sum, while downregulation of PFKFB4 and SPINK8 were associated with back pain score sum 375 and costal left pain score sum respectively (**Table S10**). Upregulation of CTNNB1, SLC2A10, SPINK8, 376 TNFSF12 and downregulation of KREMEN1 were associated with knee pain score measures. 377 378 Within the stratified BMI groups, many genes were associated with various pain scores and locations. 379 MST1 downregulation was associated with highest neck pain score in Mid BMI individuals (Multiple 380 tissues,  $p < 4.00 \times 10^{-5}$ ). Among the Low BMI individuals, six genes were associated with abdomen pain 381 score sum: CLIC1, EBF3, GPR75, NICN1, SLC2A10 and TNFSF12 (Table S10). Upregulation of ARIH2, 382 MST1 and NICN1 in Low BMI individuals was associated with right leg pain score sum. In High BMI 383 individuals, CTNNB1, KREMEN1, SLC2A10, SPINK8 and TNFSF12 were associated with measures of 384 knee pain, and *PFKFB4*, *SUOX* and *NICN1* were associated with back pain, head pain, and ankle pain 385 respectively. All summary statistics for pain score by location can be found in Table S10.

386

387 Pulse

Pulse measurements of beats per minute (bpm) were measured as the other vital sign continuous
 measurements as highest ever, lowest ever, mean and variance (Supplemental Methods).

390 Downregulation of two genes, *NCKIPSD* and *TNFSF12*, were associated with mean pulse and pulse

- 391 variance respectively in the overall cohort (Colon Transverse-*NCKIPSD*, p=1.60 x 10<sup>-4</sup>; Brain Substantia
- 392 nigra-*TNFSF12*, p=9.20 x 10<sup>-4</sup>). Among individuals of Low BMI, a different set of genes is associated with
- 393 measures of pulse. Downregulation of *ARIH2* was associated with highest pulse, while downregulation of
- 394 *MST1R* and *RNF123* was associated with mean pulse (Low-Liver-ARIH2, p=2.57 x 10<sup>-4</sup>; Low-Colon
- 395 Sigmoid-*MST1R*, p=5.81 x  $10^{-4}$ ; Low-Pituitary-*RNF123*, p=5.65 x  $10^{-4}$ ). Upregulation of *ARIH2OS* was
- associated with mean pulse in Low BMI individuals as well (Low-Nerve Tibial-ARIH2OS, p=7.52 x 10<sup>-4</sup>).
- 397 Full summary statistics are located in **Table S6**.
- 398

# 399 Pulse Oximetry

AN-GReX was not significantly associated with measures of pulse oximetry in the overall Bio*Me*<sup>TM</sup> cohort, however, when we stratified by BMI, we did see significant associations of AN-GReX with pulse oximetry within the High and Low BMI individuals. Downregulation of *MGMT* was associated with mean pulse oximetry measurements in High BMI individuals (High-Brain Cerebellar Hemisphere-*MGMT*, p=6.84 x 10<sup>-</sup> 404 <sup>4</sup>), while downregulation of *GPX1* and upregulation of *ARIH2* were associated with pulse oximetry variance in Low BMI individuals (Low-Ovary-*GPX1*, p=1.95 x 10<sup>-4</sup>; Low-Brain Amygdala-*ARIH2*, p=9.03 x 10<sup>-4</sup>). Full summary statistics are located in **Table S6**.

407

## 408 *Respirations*

409 Associations of AN-GReX with respirations, or breaths per minute, were measured using highest ever,

410 lowest ever, mean and variance for the respiration phenotypes (**Supplemental Methods**).

411 Downregulation of *ARIH2*, *CCDC36*, and *MST1R*, and upregulation of *CCDC71*, *GPX1*, *RBM6* and

412 *WDR6* were associated with measures of highest ever respiration rate (Multiple tissues,  $p < 9.84 \times 10^{-4}$ ,

- 413 **Table S6**). Additionally, downregulation of *CCDC36* and *P4HTM*, and upregulation of *GPX1*, were
- 414 associated with mean respiration rate among the overall cohort (Multiple tissues,  $p < 8.53 \times 10^{-4}$ ). Among
- the BMI stratified groups, we find that downregulation of *GPX1* and upregulation of *NICN1* is associated
- 416 with lowest ever respiration rates in High BMI individuals (Multiple tissues,  $p < 8.99 \times 10^{-4}$ ). Among Low
- BMI individuals, we see similar patterns of association of AN-GReX with respirations as we saw in the

- 418 overall cohort. Downregulation of ARIH2, NCKIPSD, and CCDC36, and upregulation of CCDC71 and
- 419 WDR6 are associated with highest respiration rate in the Low BMI individuals (Multiple tissues, p<9.93 x
- 420  $10^{-4}$ ). Full summary statistics are located in **Table S6**.
- 421

### 422 Temperature

- Temperature measurements were standardized to degrees Celsius (**Supplemental Methods**), and highest ever, lowest ever, mean and variance calculated. In the overall cohort, upregulation of *MGMT* was associated with mean temperature (Testis-*MGMT*, p=5.63 x  $10^{-4}$ ). Among individuals in the Mid BMI group, downregulation of *EBF3* was associated with highest ever temperature (DLFPC-*EBF3*, p=7.24 x  $10^{-4}$ ; Ovary-*EBF3*, p=7.15 x  $10^{-4}$ ). Full summary statistics are located in **Table S6**.
- 428

# 429 Weight (Additional results)

Regression lines (with confidence intervals) for individual *CLIC1*-GReX plotted against highest and lowest
recorded weight measures are shown in **Figure S16 and S17**.

432

433 Multiple genes were associated with weight change over time, which was measured by kg change per 434 year, in all four BMI groups. Downregulation of ARIH2, NCKIPSD, NDUFAF3 and P4HTM and 435 upregulation of WDR6 were associated with weight change over time in Overall, High and Low BMI 436 groups in multiple tissues (Figure S4, Table 3). Downregulation of RNF123 was associated with weight 437 change over time in the overall cohort and in individuals with High BMI (Overall-Uterus-RNF123, p=3.18 x 438  $10^{-4}$ ; High-Artery Aorta-*RNF123*, p=3.59 x  $10^{-4}$ ), and upregulation of *RNF123* was associated with weight 439 change in individuals with Mid and Low BMI (Mid-Brain Amygdala-*RNF123*, p=8.91 x 10<sup>-5</sup>; Mid-Cells Transformed Fibroblasts-*RNF123*, p=2.90 x 10<sup>-4</sup>; Low-Vagina-*RNF123*, p=5.16 x 10<sup>-4</sup>). Upregulation of 440 441 CCDC71 and DHFR2, and downregulation of DALRD3 were associated with weight change over time in 442 High and Low BMI individuals (High-Brain Cerebellar Hemisphere-CCDC71, p=4.71 x 10<sup>-4</sup>; High-Brain Cerebellum-CCDC71,  $p=1.67 \times 10^{-4}$ ; High-Spleen-CCDC71,  $p=2.43 \times 10^{-4}$ ; High-Thyroid-CCDC71, 443  $p=7.53 \times 10^{-4}$ ; Low-Tibial Nerve-CCDC71,  $p=6.82 \times 10^{-4}$ ; High-DGN Whole Blood-DHFR2,  $p=3.47 \times 10^{-4}$ ; 444 Low-DGN Whole Blood-DHFR2, p=7.48 x 10<sup>-4</sup>; High-Multiple tissues-DALRD3, p<8.21 x 10<sup>-4</sup>; Low-Brain 445

446 Cerebellum-*DALRD3*, p=5.85 x 10<sup>-4</sup>; Low-Esophagus Gastroesophageal Junction-*DALRD3*, p=5.01 x 10<sup>-4</sup> 447 <sup>4</sup>). In individuals with High BMI, downregulation of *C3orf62*, *CCDC36*, *CELSR3* and *PROS1* were 448 associated with weight change over time (High-DLPFC-*C3orf62*, p=8.59 x 10<sup>-4</sup>; High-Adipose Visceral 449 Omentum-*C3orf62*, p=6.45 x 10<sup>-4</sup>; High-DGN Whole Blood-*C3orf62*; p=7.19 x 10<sup>-4</sup>; High-DGN Whole 450 Blood-*CCDC36*, p=3.05 x 10<sup>-6</sup>; High-Subcutaneous Adipose-*CCDC36*, p= p=1.40 x 10<sup>-5</sup>; High-Tibial 451 Nerve-*CELSR3*, p=1.09 x 10<sup>-4</sup>; High-Whole Blood-*PROS1*, p=3.46 x 10<sup>-4</sup>). Full summary associations of 452 AN-GReX with weight change over time are shown in **Table 3**.

453

# 454 **Distribution of CLIC1-GReX by BMI**

To assess whether our BMI-group specific *CLIC1*-GReX associations are driven by differences in the distribution of GReX measures in these BMI subgroups, we tested for pairwise differences in the distribution of *CLIC1*-GReX for four tissues (Breast Mammary Tissue, Spleen, Subcutaneous Adipose and Whole Blood) using the Kolmogorov-Smirnov test (**Figure S18**). We found no significant difference in the distribution of *CLIC1*-GReX across BMI groups for any tissue ( $p_{Significance}<0.0167$ ; Breast Mammary Tissue,  $p_{KS}>0.0495$ ; Spleen,  $p_{KS}>0.0368$ ; Subcutaneous Adipose,  $p_{KS}>0.9262$ ; Whole Blood,  $p_{KS}>0.2726$ ).

# 463 SUPPLEMENTARY FIGURES AND TABLES

464

Figure S1: BMI stratification of the BioMe<sup>™</sup> cohort. We stratified the BioMe<sup>™</sup> individuals into three
BMI groups: High, Mid and Low, based on the distribution of BMI within each ancestry by sex. Individuals
whose BMI fell above the 3<sup>rd</sup> quartile of BMI distribution were assigned to the High BMI group, those
whose BMI fell below the 1<sup>st</sup> quartile were assigned to Low, and those between the 1<sup>st</sup> and 3<sup>rd</sup> quartiles of
the distribution were assigned to the Mid BMI group.

470

Figure S2: Distribution of BMI by BioMe<sup>™</sup> ancestry and sex. BMI distributions are plotted by sex
(female, male) for each ancestry group. Ancestry is coded as: AA (African), EA (European), ESA (East
Asian), HA (Hispanic), NA (Native American), SAS (South Asian).

474

Figure S3: Forest plot of Overall weight change over time associations with AN-GReX. Effect estimate and 95% CI measures for AN-GReX (Gene-Tissue) associated with the measurement of weight change over time (measured as kg/year) in the overall  $BioMe^{TM}$  cohort. Tissue-specific significance threshold set at p<0.001.

479

480 Figure S4: Forest plot of Overall weight change over time associations with AN-GReX across three

481 **BMI groups**. Effect estimate and 95% CI measures for AN-GReX (Gene-Tissue) associated with the

482 measurement of weight change over time (measured as kg/year) in four BMI groups: Overall, High BMI,

483 Mid BMI and Low BMI. Tissue-specific significance threshold set at p<0.001.

484

Figure S5: Forest plot of Encounter Diagnosis associations across BMI groups. Effect estimates
and 95% CI for the associations of AN-GReX with Encounter Diagnosis ICD-10 codes across the four
BMI groups: Overall, High BMI, Mid BMI and Low BMI. Diagnosis code and description, as well as GeneTissue of association, given on the Y-axis. Experiment-wide significance threshold set at p<3.06 x 10<sup>-7</sup>.

489

490 **Figure S6: Forest plot of Phecode associations across BMI groups.** Effect estimates and 95% CI for

the associations of AN-GReX with phecodes across the four BMI groups: Overall, High BMI, Mid BMI and

492 Low BMI. Phecode and description, as well as Gene-Tissue of association, given on the Y-axis.

493 Experiment-wide significance threshold set at  $p < 3.06 \times 10^{-7}$ .

494

495 Figure S7: Forest plot of Substance Use AN-GReX associations across BMI groups. Effect

496 estimates and 95% CI for the associations of AN-GReX with substance use phenotypes across the four

497 BMI groups: Overall, High BMI, Mid BMI and Low BMI. Tissue-specific significance threshold set at 498 p<0.001.

499

500 Figure S8: Forest plot of *CLIC1*-Spleen association with Glucagon medication across BMI groups.

501 Effect estimates and 95% CI for the associations of *CLIC1*-Spleen GReX with Glucagon medication

502 across the four BMI groups: Overall, High BMI, Mid BMI and Low BMI. Filled circles indicate Bonferroni-

503 significant associations. Tissue-specific significance threshold set at p<5.26 x  $10^{-5}$ .

504

505 Figure S9: Graphical depiction of S-PrediXcan and PrediXcan transcriptomic imputation and 506 pheWAS analyses. We used S-PrediXcan predictor models for 50 different tissue types to impute 507 genetically-regulated gene expression (GReX) in the Watson, et. al, 2019 AN GWAS and found 47 genes 508 whose GReX was associated with Anorexia Nervosa. We then imputed GReX for those 47 AN genes in 509 our BioMe<sup>™</sup> cohort and performed a phenome-wide association study (pheWAS) across available EHR 510 phenotypes. The pheWAS analyses were run within each ancestral population and then meta-analyzed 511 using an inverse-variance approach in METAL. Secondary analyses included stratifying individuals in 512 Bio*Me* by BMI and running the pheWAS analyses within each BMI group.

Figure S10: Descriptive statistics for continuous measures of substance use. Continuous
phenotypes for alcohol, illicit drug and tobacco use. Alcohol use was measured as number of ounces of
alcohol consumed per week, Illicit drug use was measured as number of times used (frequency), and
tobacco use was measured as number of years usage of tobacco and number of packs of cigarettes
smoked per day.

519

Figure S11: Descriptive statistics for continuous OBGYN outcome phenotypes. Counts for the
presence of nine OBGYN phenotypes: (1) Current pregnancy (2) Parity (number of pregnancies with
outcome of live birth) (3) Gravida (number of pregnancies regardless of birth outcome) (4) Births to term
(5) Preterm births (6) Ectopic pregnancies (7) Abortion (8) Spontaneous abortion (miscarriage) (9)
Therapeutic abortion.

525

Figure S12: Descriptive statistics for vital sign measurement phenotypes. Vital sign measurements
for blood pressure (systolic, diastolic and pulse pressure), height (cm), pulse (beats per minute), pulse
oximetry (%), respirations (breaths per minute) and temperature (degrees Celsius).

529

Figure S13: Descriptive statistics of weight phenotypes. Distribution of weight measurements (in kg)
of highest recorded and lowest recorded weight in Bio*Me*<sup>™</sup>. Weight change over time was measured as
average kg change per year.

533

Figure S14: Descriptive statistics for pain score and pain location phenotypes. (A) Histograms of pain score (regardless of pain location) recorded on a 0 to 10 scale; measurements used for pheWAS analyses included highest recorded pain score, mean pain score and sum of all pain score measurements. Mean pain score is indicated by the dotted line. (B) Violin plots of pain score by location measured as highest recorded pain score, mean pain score, and sum of pain scores for each pain location. Mean pain score measurements for each phenotype is indicated by the red dot. 540

#### 541 Figure S15: Manhattan plot of association of Personal History phenotypes with AN-GReX for four

542 **BMI groups.** Personal History phenotypes (N=35; X-axis) and association with AN-GRex (-log10(p) on Y-

- 543 axis) for four BMI groups: Overall, High BMI, Mid BMI, and Low BMI. Experiment-wide p=2.86 x 10<sup>-5</sup>;
- 544 Tissue-specific  $p=1.43 \times 10^{-3}$ .
- 545

#### 546 Figure S16: Regression plots for individual *CLIC1*-GReX versus lowest and highest weight

547 **measures**. Linear regression model lines with 95% confidence intervals for individual CLIC1-GReX

548 measures for (A) Subcutaneous Adipose, (B) Breast Mammary Tissue, (C) Spleen, and (D) Whole Blood

549 tissues for lowest recorded weight and highest recorded weight measures (kg). Forest plots of effect

- 550 estimates for associations of *CLIC1*-GReX with lowest and highest recorded weight.
- 551

### 552 Figure S17: CLIC1-GReX versus lowest recorded weight measurement (kg). (A) Individual CLIC1-

553 GReX measures versus lowest recorded weight measurements for breast and spleen tissues with

regression line and 95% confidence interval. (B) Individual *CLIC1*-GReX measures versus lowest

- recorded weight measurements (kg) for Breast Mammary tissue and Spleen, with regression line only and
  95% confidence interval.
- 557
- 558 **Figure S18: Distribution of** *CLIC1***-GReX by BMI group**. Density plots of *CLIC1*-GReX for (A) Breast
- 559 Mammary, (B) Spleen, (C) Subcutaneous Adipose, and (D) Whole Blood tissues by three BMI groups,

High, Mid and Low. P value for KS test for significance shown for each tissue.

561

## 562 Table S1: Bonferroni-corrected significance thresholds for each tissue model tested for S-

FrediXcan. Indicates number of genes tested per tissue, with p value for tissue-specific significance set
 at p=0.05/N<sub>Genes</sub>.

565

Table S2: BMI stratification values by BioMe<sup>™</sup> ancestry. BMI values used for determining assignment
 to High, Mid or Low BMI groups for each ancestral population and sex. High BMI range indicates the

values above the 3<sup>rd</sup> quartile. Low BMI indicates the BMI values below the 1<sup>st</sup> quartile, and Mid shows the
 BMI range between the 1<sup>st</sup> and 3<sup>rd</sup> quartiles of BMI distribution.

570

Table S3: Sample numbers for each BMI group. Sample numbers indicated for each BMI group after
stratification. Ancestry is coded as: AA (African), EA (European), ESA (East Asian), HA (Hispanic), NA
(Native American), SAS (South Asian).

574

# 575 Table S4: Full summary statistics for S-PrediXcan transcriptomic imputation of the PGC-AN

- 576 **GWAS**<sup>9</sup>. Gene-level summary statistics for transcriptomic imputation of AN-GWAS (N<sub>Cases</sub>=16,992,
- 577 N<sub>Controls</sub>=55,525) using S-PrediXcan models for CMC DLPFC, DGN Whole Blood and 47 GTEx v7 tissues.

578

579 Table S5: AN S-PrediXcan gene summary. Summary description of 47 AN genes, including information
580 on previous GWAS trait associations.

581

Table S6: Vital sign pheWAS results. GReX-Tissue-Phenotype associations for Vital Sign phenotypes
(Blood pressure, Height, Pulse, Pulse Oximetry, Respirations, Temperature and Weight) across all BMI
groups: Overall, High, Mid, and Low. Tissue-specific threshold set at p<0.001.</li>

585

**Table S7: Encounter Diagnosis pheWAS results**. GReX-Tissue-Phenotype associations for encounter diagnosis phenotypes (N=2,178) across all BMI groups: Overall, High, Mid, and Low. Experiment-wide p value threshold  $p= 3.06 \times 10^{-7}$ ; Tissue-specific threshold  $p= 2.30 \times 10^{-5}$ .

589

- 590 **Table S8: Phecode pheWAS results**. GReX-Tissue-Phenotype associations for phecode phenotypes
- 591 (N=1,093) across all BMI groups: Overall, High, Mid, and Low. Experiment-wide p value threshold p =

592  $3.06 \times 10^{-7}$ ; Tissue-specific threshold p= 4.57 x  $10^{-5}$ .

594	Table S9: Social History pheWAS results. GReX-Tissue-Phenotype associations for Social History
595	phenotypes (Alcohol, Illicit Drug and Tobacco use; Sexual History) across all BMI groups: Overall, High,
596	Mid, and Low. Tissue-specific threshold set at p<0.001.
597	
598	Table S10: Pain Score and Location pheWAS results. GReX-Tissue-Phenotype associations for Pain
599	score and location phenotypes across all BMI groups: Overall, High, Mid, and Low. Tissue-specific
600	threshold set at p<0.002.
601	
602	Table S11: Medication pheWAS results. GReX-Tissue-Phenotype associations for medication
603	phenotypes (N=951) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific threshold set at
604	p<5.26 x 10⁻⁵.
605 606 607	Table S12: Allergy pheWAS results. GReX-Tissue-Phenotype associations for allergy phenotypes
608	(N=113) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific threshold set at p<4.42 x 10 <sup>-</sup>
609	
610	
611	Table S13: Encounter orders pheWAS results. GReX-Tissue-Phenotype associations for Encounter
612	order phenotypes (N=1,609) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific
613	threshold set at p<3.11 x $10^{-5}$ .
614	
615	Table S14: Family History pheWAS results. GReX-Tissue-Phenotype associations for Family history
616	phenotypes (N=144) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific threshold set at
617	p<3.47 x 10 <sup>-4</sup> .
618	
619	Table S15: Personal History pheWAS results. GReX-Tissue-Phenotype associations for Personal
620	history phenotypes (N=35) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific threshold
621	set at p<0.001.
622	

623	Table S16: OBGYN pheWAS results. GReX-Tissue-Phenotype associations for OBGYN phenotypes
624	(N=9) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific threshold set at p<0.006.
625	
626	Table S17: Full pheWAS summary results. GReX-Tissue-Phenotype associations for all pheWAS
627	phenotypes (N=6,000+) across all BMI groups: Overall, High, Mid, and Low.
628	
629	Table S18: Sample Numbers for OBGYN outcomes. Categorical OBGYN phenotypes. Ancestry is
630	coded as: AA (African), EA (European), ESA (East Asian), HA (Hispanic), SAS (South Asian).
631	
632	Table S19: Sample numbers for Alcohol use categorical phenotypes. Categorical phenotypes for
633	alcohol use in BioMe™: Never used, Not currently using, Not used, Yes using and not asked. Ancestry is
634	coded as: AA (African), EA (European), ESA (East Asian), HA (Hispanic), SAS (South Asian).
635	
636	Table S20: Sample numbers for Illicit drug use categorical phenotypes. Categorical phenotypes for
637	illicit drug use in Bio <i>Me</i> ™. Ancestry is coded as: AA (African), EA (European), ESA (East Asian), HA
638	(Hispanic), SAS (South Asian).
639	
640	Table S21: Sample numbers for categorical tobacco use phenotypes. Categorical phenotypes for
641	tobacco use in Bio <i>Me</i> ™: Tobacco use and type. Ancestry is coded as: AA (African), EA (European), ESA
642	(East Asian), HA (Hispanic), SAS (South Asian).
643	
644	Table S22: Sample numbers for categorical sexual history phenotypes. Categorical phenotypes for
645	sexual history in Bio <i>Me</i> ™. Ancestry is coded as: AA (African), EA (European), ESA (East Asian), HA
646	(Hispanic), SAS (South Asian).

1

#### Eating Disorders Working Group of the Psychiatric Genomics Consortium

2

Roger A. H. Adan<sup>1-3</sup>. Lars Alfredsson<sup>4</sup>. Tetsuva Ando<sup>5</sup>. Ole A. Andreassen<sup>6</sup>. Harald Aschauer<sup>7</sup>. 3 Jessica H. Baker<sup>8</sup>, Vladimir Bencko<sup>9</sup>, Andrew W. Bergen<sup>10,11</sup>, Wade H. Berrettini<sup>12</sup>, Andreas 4 5 Birgegård<sup>13</sup>, Joseph M. Boden<sup>14</sup>, Ilka Boehm<sup>15</sup>, Vesna Boraska Perica<sup>16,17</sup>, Harry Brandt<sup>18</sup>, Gerome Breen<sup>19,20</sup>, Julien Bryois<sup>13</sup>, Cynthia M. Bulik<sup>8,13, 21</sup>, Roland Burghardt<sup>22</sup>, Laura Carlberg<sup>23</sup>, 6 Matteo Cassina<sup>24</sup>, Sven Cichon<sup>25-27</sup>, Maurizio Clementi<sup>24</sup>, Jonathan R. I. Coleman<sup>19,20</sup>, Roger D. 7 Cone<sup>28</sup>, Philippe Courtet<sup>29</sup>, Steven Crawford<sup>18</sup>, Scott Crow<sup>30</sup>, James J. Crowley<sup>31,32</sup>, Unna N. 8 Danner<sup>2</sup>, Oliver S. P. Davis<sup>33-35</sup>, Martina deZwaan<sup>36</sup>, George Dedoussis<sup>37</sup>, Daniela Degortes<sup>38</sup>, 9 Janiece E. DeSocio<sup>39</sup>, Danielle M. Dick<sup>40-42</sup>, Dimitris Dikeos<sup>43</sup>, Christian Dina<sup>44</sup>, Monika Dmitrzak-10 Weglarz<sup>45</sup>, Elisa Docampo<sup>46-48</sup>, Laramie E. Duncan<sup>49</sup>, Philibert Duriez<sup>50,51</sup>, Karin Egberts<sup>52</sup>, Stefan 11 Ehrlich<sup>15</sup>, Geòrgia Escaramís<sup>46-48</sup>, Tõnu Esko<sup>53,54</sup>, Thomas Espeseth<sup>55,56</sup>, Xavier Estivill<sup>46-48,57</sup>, 12 13 Anne Farmer<sup>19</sup>, Angela Favaro<sup>38</sup>, Fernando Fernández-Aranda<sup>58,59</sup>, Manfred M. Fichter<sup>60,61</sup>, Krista 14 Fischer<sup>53</sup>, James A. B. Floyd<sup>62</sup>, Manuel Föcker<sup>63</sup>, Lenka Foretova<sup>64</sup>, Andreas J. Forstner<sup>27,65,66</sup>, Monica Forzan<sup>24</sup>, Christopher S. Franklin<sup>16</sup>, Steven Gallinger<sup>67</sup>, Giovanni Gambaro<sup>68</sup>, Héléna A. 15 Gaspar<sup>19,20</sup>, Ina Giegling<sup>69</sup>, Paola Giusti-Rodríquez<sup>31</sup>, Fragiskos Gonidakis<sup>43</sup>, Scott Gordon<sup>70</sup>, 16 Philip Gorwood<sup>50,51</sup>, Monica Gratacos Mayora<sup>46-48</sup>, Jakob Grove<sup>71-74</sup>, Sébastien Guillaume<sup>29</sup>, Yiran 17 Guo<sup>75</sup>, Hakon Hakonarson<sup>75,76</sup>, Katherine A. Halmi<sup>77</sup>, Ken B. Hanscombe<sup>19</sup>, Konstantinos 18 Hatzikotoulas<sup>16,78</sup>, Joanna Hauser<sup>79</sup>, Johannes Hebebrand<sup>80</sup>, Sietske G. Helder<sup>19,81</sup>, Anjali 19 20 Henders<sup>82</sup>, Stefan Herms<sup>25,26</sup>, Beate Herpertz-Dahlmann<sup>83</sup>, Wolfgang Herzog<sup>84</sup>, Anke Hinney<sup>80</sup>, L. 21 John Horwood<sup>14</sup>, Christopher Hübel<sup>19,85</sup>, Laura M. Huckins<sup>86-89</sup>, James I. Hudson<sup>90</sup>, Hartmut Imgart<sup>91</sup>, Hidetoshi Inoko<sup>92</sup>, Vladimir Janout<sup>93</sup>, Susana Jiménez-Murcia<sup>58,59</sup>, Craig Johnson<sup>94</sup>, 22 Jessica S. Johnson<sup>86,87</sup>, Jennifer Jordan<sup>95,96</sup>, Antonio Julià<sup>97</sup>, Gursharan Kalsi<sup>19</sup>, Deborah 23 Kaminská<sup>98</sup>, Allan S. Kaplan<sup>99-101</sup>, Jaakko Kaprio<sup>102</sup>, Leila Karhunen<sup>103</sup>, Andreas Karwautz<sup>104</sup>, 24 Martien J. H. Kas<sup>1,105</sup>, Walter H. Kaye<sup>106</sup>, James L. Kennedy<sup>99-101</sup>, Martin A. Kennedy<sup>107</sup>, Anna 25 Keski-Rahkonen<sup>108</sup>, Kirsty Kiezebrink<sup>109</sup>, Youl-Ri Kim<sup>110</sup>, Katherine M. Kirk<sup>111</sup>, Lars Klareskog<sup>112</sup>, 26 27 Kelly L. Klump<sup>113</sup>, Gun Peggy S. Knudsen<sup>114</sup>, Maria C. La Via<sup>8</sup>, Mikael Landén<sup>13,115</sup>, Janne T. Larsen<sup>72,85,116</sup>, Stephanie Le Hellard<sup>117,118</sup>, Virpi M. Leppä<sup>13</sup>, Dong Li<sup>75</sup>, Paul Lichtenstein<sup>13</sup>, Lisa 28

Lilenfeld<sup>119</sup>, Bochao Danae Lin<sup>1</sup>, Jolanta Lissowska<sup>120</sup>, Astri J. Lundervold<sup>121</sup>, Jurjen Luykx<sup>1</sup>, 29 Pierre J. Magistretti<sup>122-123</sup>, Mario Maj<sup>124</sup>, Katrin Mannik<sup>53,125</sup>, Sara Marsal<sup>97</sup>, Christian R. 30 Marshall<sup>126</sup>, Nicholas G, Martin<sup>70</sup>, Manuel Mattheisen<sup>32,71,127,128</sup>, Morten Mattingsdal<sup>6</sup>, Sara 31 McDevitt<sup>129,130</sup>, Peter McGuffin<sup>19</sup>, Sarah E. Medland<sup>111</sup>, Andres Metspalu<sup>53,131</sup>, Ingrid 32 Meulenbelt<sup>132</sup>, Nadia Micali<sup>133,134</sup>, James Mitchell<sup>135</sup>, Karen Mitchell<sup>136,137</sup>, Alessio Maria 33 Monteleone<sup>124</sup>, Palmiero Monteleone<sup>138</sup>, Grant W. Montgomery<sup>82,111,139</sup>, Preben Bo 34 Mortensen<sup>72,85,116</sup>, Melissa A. Munn-Chernoff<sup>8</sup>, Benedetta Nacmias<sup>140,141</sup>, Marie Navratilova<sup>64</sup>, 35 Ioanna Ntalla<sup>37</sup>, Catherine M. Olsen<sup>142</sup>, Roel A. Ophoff<sup>143,144</sup>, Julie O'Toole<sup>145</sup>, Leonid 36 Padyukov<sup>112</sup>, Aarno Palotie<sup>54,102,146</sup>, Jacques Pantel<sup>147</sup>, Hana Papezova<sup>98</sup>, Richard Parker<sup>111</sup>, John 37 F. Pearson<sup>148</sup>, Nancy L. Pedersen<sup>13</sup>, Triinu Peters<sup>80</sup>, Liselotte V. Petersen<sup>72,85,116</sup>, Dalila Pinto<sup>87</sup>, 38 Kirstin L. Purves<sup>19</sup>, Anu Raevuori<sup>108,149</sup>, Nicolas Ramoz<sup>51</sup>, Ted Reichborn-Kjennerud<sup>114,150</sup>, Valdo 39 Ricca<sup>151</sup>, Samuli Ripatti<sup>152</sup>, Stephan Ripke<sup>153-155</sup>, Marion Roberts<sup>19</sup>, Alessandro Rotondo<sup>156</sup>, Dan 40 41 Rujescu<sup>69</sup>, Filip Rybakowski<sup>157</sup>, Paolo Santonastaso<sup>158</sup>, André Scherag<sup>159</sup>, Stephen W. 42 Scherer<sup>160,161</sup>, Ulrike Schmidt<sup>162</sup>, Nicholas J. Schork<sup>163</sup>, Alexandra Schosser<sup>164</sup>, Jochen Seitz<sup>83</sup>, Lenka Slachtova<sup>165</sup>, P. Eline Slagboom<sup>132</sup>, Margarita C. T. Slof-Op't Landt<sup>166,167</sup>, Agnieszka 43 Slopien<sup>168</sup>, Nicole Soranzo<sup>16,169-171</sup>, Sandro Sorbi<sup>140,141</sup>, Lorraine Southam<sup>16,78</sup>, Vidar W. 44 45 Steen<sup>172,173</sup>, Michael Strober<sup>174,175</sup>, Garret D. Stuber<sup>8,176</sup>, Patrick F. Sullivan<sup>8,13,31</sup>, Beata Świątkowska<sup>177</sup>, Jin P. Szatkiewicz<sup>31</sup>, Ioanna Tachmazidou<sup>16</sup>, Friederike I. Tam<sup>15,178</sup>, Elena 46 Tenconi<sup>38</sup>, Laura M. Thornton<sup>8</sup>, Alfonso Tortorella<sup>179</sup>, Federica Tozzi<sup>180</sup>, Janet Treasure<sup>19</sup>, Artemis 47 48 Tsitsika<sup>181</sup>, Marta Tyszkiewicz-Nwafor<sup>168</sup>, Konstantinos Tziouvas<sup>182</sup>, Annemarie van Elburg<sup>2,183</sup>, Eric F. van Furth<sup>166,167</sup>, Tracey D. Wade<sup>184</sup>, Gudrun Wagner<sup>104</sup>, Esther Walton<sup>15</sup>, Hunna J. 49 Watson<sup>8,185,186</sup>, Thomas Werge<sup>187</sup>, David C. Whiteman<sup>142</sup>, H-Erich Wichmann<sup>188</sup>, Elisabeth 50 Widen<sup>102</sup>, D. Blake Woodside<sup>100,101,189,190</sup>, Jiayi Xu<sup>86</sup>, Shuyang Yao<sup>13</sup>, Zeynep Yilmaz<sup>8,13,31,85</sup>, 51 Eleftheria Zeggini<sup>16,78,191</sup>. Stephanie Zerwas<sup>8</sup>. Stephan Zipfel<sup>192,193</sup>. 52 53 54

56 <sup>1</sup>Brain Center Rudolf Magnus, Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, The 57 Netherlands.<sup>2</sup>Center for Eating Disorders Rintveld, Altrecht Mental Health Institute, Zeist, The Netherlands.<sup>3</sup>Sahlgrenska 58 Academy, University of Gothenburg, Gothenburg, Sweden.<sup>4</sup>Institute of Environmental Medicine, Karolinska Institutet, 59 Stockholm, Sweden. <sup>5</sup>Department of Behavioral Medicine, National Institute of Mental Health, National Center of 60 Neurology and Psychiatry, Kodaira, Tokyo, Japan. <sup>6</sup>NORMENT KG Jebsen Centre, Division of Mental Health and 61 Addiction, University of Oslo, Oslo University Hospital, Oslo, Norway.<sup>7</sup>Biopsychosocial Corporation, Vienna, Austria. 62 <sup>8</sup>Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. <sup>9</sup>First Faculty of 63 Medicine, Institute of Hygiene and Epidemiology, Charles University, Prague, Czech Republic.<sup>10</sup>BioRealm, LLC, Walnut, 64 California, USA. <sup>11</sup>Oregon Research Institute, Eugene, Oregon, USA.<sup>12</sup>Department of Psychiatry, Center for Neurobiology 65 and Behavior, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.<sup>13</sup>Department of 66 Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.<sup>14</sup>Christchurch Health and Development 67 Study, University of Otago, Christchurch, New Zealand.<sup>15</sup>Division of Psychological and Social Medicine and 68 Developmental Neurosciences, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany.<sup>16</sup>Wellcome 69 Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.<sup>17</sup>Department of Medical Biology, School of 70 Medicine, University of Split, Split, Croatia.<sup>18</sup>The Center for Eating Disorders at Sheppard Pratt, Baltimore, Maryland, 71 USA.<sup>19</sup>Institute of Psychiatry, Psychology and Neuroscience, Social, Genetic and Developmental Psychiatry (SGDP) 72 Centre, King's College London, London, UK.<sup>20</sup>National Institute for Health Research Biomedical Research Centre, King's 73 College London and South London and Maudsley National Health Service Trust, London, UK.<sup>21</sup>Department of Nutrition, 74 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.<sup>22</sup>Klinikum Frankfurt/Oder, Frankfurt, 75 Germany.<sup>23</sup>Medical University of Vienna, Vienna, Austria.<sup>24</sup>Clinical Genetics Unit, Department of Woman and Child 76 Health, University of Padova, Padova, Italy.<sup>25</sup>Institute of Medical Genetics and Pathology, University Hospital Basel, 77 Basel, Switzerland.<sup>26</sup>Department of Biomedicine, University of Basel, Basel, Switzerland.<sup>27</sup>Institute of Neuroscience and 78 Medicine (INM-1), Research Center Juelich, Juelich, Germany.<sup>28</sup>Life Sciences Institute and Department of Molecular and 79 Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA.<sup>29</sup>Department of Emergency Psychiatry and 80 Post-Acute Care, CHRU Montpellier, University of Montpellier, Montpellier, France.<sup>30</sup>Department of Psychiatry, University 81 of Minnesota, Minneapolis, Minnesota, USA.<sup>31</sup>Department of Genetics, University of North Carolina at Chapel Hill, Chapel 82 Hill, North Carolina, USA.<sup>32</sup>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.<sup>33</sup>MRC 83 Integrative Epidemiology Unit, University of Bristol, Bristol, UK.<sup>34</sup>Bristol Medical School, University of Bristol, Bristol, 84 UK.<sup>35</sup>The Alan Turing Institute, London, UK.<sup>36</sup>Department of Psychosomatic Medicine and Psychotherapy, Hannover 85 Medical School, Hannover, Germany.<sup>37</sup>Department of Nutrition and Dietetics, Harokopio University, Athens, 86 Greece.<sup>38</sup>Department of Neurosciences, University of Padova, Padova, Italy.<sup>38</sup>College of Nursing, Seattle University, 87 Seattle, Washington, USA.<sup>40</sup>Department of Psychology, Virginia Commonwealth University, Richmond, Virginia, 88 USA.<sup>41</sup>College Behavioral and Emotional Health Institute, Virginia Commonwealth University, Richmond, Virginia, 89 USA.<sup>42</sup>Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, Virginia, USA.<sup>43</sup>First 90 Department of Psychiatry, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens,

91 Greece.<sup>44</sup>L'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.<sup>45</sup>Department of Psychiatric Genetics, 92 Poznan University of Medical Sciences, Poznan, Poland.<sup>46</sup>Barcelona Institute of Science and Technology, Barcelona, 93 Spain.<sup>47</sup>Universitat Pompeu Fabra, Barcelona, Spain.<sup>48</sup>Centro de Investigación Biomédica en Red en Epidemiología y 94 Salud Pública (CIBERESP), Barcelona, Spain.<sup>49</sup>Department of Psychiatry and Behavioral Sciences, Stanford University, 95 Stanford, California, USA.<sup>50</sup>GHU Paris Psychiatrie et Neurosciences, CMME, Paris Descartes University, Paris, 96 France.<sup>51</sup>INSERM U1266, Institute of Psychiatry and Neurosciences, Paris, France.<sup>52</sup>Department of Child and Adolescent 97 Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Centre for Mental Health, Würzburg, 98 Germany.<sup>53</sup>Estonian Genome Center, University of Tartu, Tartu, Estonia.<sup>54</sup>Program in Medical and Population Genetics, 99 Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, 100 USA.<sup>55</sup>Department of Psychology, University of Oslo, Oslo, Norway.<sup>56</sup>Bjørknes College, Oslo, Norway.<sup>57</sup>Genomics and 101 Disease, Bioinformatics and Genomics Programme, Centre for Genomic Regulation, Barcelona, Spain.<sup>58</sup>Department of 102 Psychiatry, University Hospital of Bellvitge – IDIBELL and CIBERobn, Barcelona, Spain.<sup>59</sup>Department of Clinical 103 Sciences, School of Medicine, University of Barcelona, Barcelona, Spain.<sup>60</sup>Department of Psychiatry and Psychotherapy, 104 Ludwig-Maximilians-University (LMU), Munich, Germany.<sup>61</sup>Schön Klinik Roseneck affiliated with the Medical Faculty of the 105 University of Munich, Munich, Germany.<sup>62</sup>Genomics plc, Genomics PLC, Oxford, UK.<sup>63</sup>Department of Child and 106 Adolescent Psychiatry, University of Münster, Münster, Germany.<sup>64</sup>Department of Cancer, Epidemiology and Genetics, 107 Masaryk Memorial Cancer Institute, Brno, Czech Republic.<sup>65</sup>Institute of Human Genetics, University of Bonn, School of 108 Medicine and University Hospital Bonn, Bonn, Germany.<sup>66</sup>Centre for Human Genetics, University of Marburg, Marburg, 109 Germany.<sup>67</sup>Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.<sup>68</sup>Division of 110 Nephrology and Dialysis, Department of Medicine, AOVR, Ospedale Maggiore, Verona, Italy.<sup>69</sup>Department of Psychiatry, 111 Psychotherapy and Psychosomatics, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.<sup>70</sup>Genetics and 112 Computational Biology Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, 113 Australia.<sup>71</sup>Department of Biomedicine, Aarhus University, Aarhus, Denmark.<sup>72</sup>The Lundbeck Foundation Initiative for 114 Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark.<sup>73</sup>Centre for Integrative Sequencing, iSEQ, Aarhus 115 University, Aarhus, Denmark.<sup>74</sup>Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark.<sup>75</sup>Center for Applied 116 Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.<sup>76</sup>Department of Pediatrics, University of 117 Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.77 Department of Psychiatry, Weill Cornell 118 Medical College, New York, New York, USA.<sup>78</sup>Institute of Translational Genomics, Helmholtz Zentrum München – German 119 Research Centre for Environmental Health, Neuherberg, Germany.<sup>79</sup>Department of Adult Psychiatry, Poznan University of 120 Medical Sciences, Poznan, Poland.<sup>80</sup>Department of Child and Adolescent Psychiatry, University Hospital Essen, 121 University of Duisburg-Essen, Essen, Germany.<sup>81</sup>Zorg op Orde, Delft, The Netherlands.<sup>82</sup>Institute for Molecular 122 Bioscience, University of Queensland, Brisbane, Queensland, Australia.<sup>83</sup>Department of Child and Adolescent Psychiatry, 123 Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany.<sup>84</sup>Department of General Internal 124 Medicine and Psychosomatics, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany,<sup>85</sup>National 125 Centre for Register-Based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark.<sup>86</sup>Pamela Sklar Division of

126 Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.<sup>87</sup>Department of Psychiatry, 127 and Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.88 Seaver 128 Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA.<sup>89</sup>Mental 129 Illness Research, Education and Clinical Centers, James J. Peters Department of Veterans Affairs Medical Center, Bronx, 130 New York, USA.<sup>90</sup>Biological Psychiatry Laboratory, McLean Hospital/Harvard Medical School, Boston, Massachusetts, 131 USA.<sup>91</sup>Eating Disorders Unit, Parklandklinik, Bad Wildungen, Germany.<sup>92</sup>Department of Molecular Life Science, Division 132 of Basic Medical Science and Molecular Medicine, School of Medicine, Tokai University, Isehara, Japan.93 Faculty of 133 Health Sciences, Palacky University, Olomouc, Czech Republic.<sup>94</sup>Eating Recovery Center, Denver, Colorado, 134 USA.95 Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.96 Canterbury District 135 Health Board, Christchurch, New Zealand.<sup>97</sup>Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, 136 Spain.<sup>98</sup>First Faculty of Medicine, Department of Psychiatry, Charles University, Prague, Czech Republic.<sup>99</sup>Centre for 137 Addiction and Mental Health, Toronto, Ontario, Canada.<sup>100</sup>Institute of Medical Science, University of Toronto, Toronto, 138 Ontario, Canada.<sup>101</sup>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.<sup>102</sup>Institute for Molecular 139 Medicine Finland FIMM, HiLIFE, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.<sup>103</sup>Institute of 140 Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, Kuopio, 141 Finland.<sup>104</sup>Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, 142 Austria.<sup>105</sup>Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The 143 Netherlands.<sup>106</sup>Department of Psychiatry, University of California San Diego, San Diego, California, USA.<sup>107</sup>Department of 144 Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.<sup>108</sup>Department of Public Health, 145 University of Helsinki, Helsinki, Finland.<sup>109</sup>Institute of Applied Health Sciences, School of Medicine, Medical Sciences and 146 Nutrition, University of Aberdeen, Aberdeen, UK.<sup>110</sup>Department of Psychiatry, Seoul Paik Hospital, Inje University, Seoul, 147 Korea.<sup>111</sup>QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.<sup>112</sup>Division of Rheumatology, 148 Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, 149 Stockholm, Sweden.<sup>113</sup>Department of Psychology, Michigan State University, East Lansing, Michigan, USA.<sup>114</sup>Department 150 of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway.<sup>115</sup>Department of Psychiatry and Neurochemistry, 151 Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, 152 Sweden.<sup>116</sup>Centre for Integrated Register-based Research (CIRRAU), Aarhus University, Aarhus, Denmark.<sup>117</sup>Dr. Einar 153 Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland 154 University Hospital, Bergen, Norway.<sup>118</sup>Department of Clinical Medicine, Laboratory Building, Haukeland University 155 Hospital, Bergen, Norway, <sup>119</sup>The Chicago School of Professional Psychology, Washington D.C., USA, <sup>120</sup>Department of 156 Cancer Epidemiology and Prevention, M. Sklodowska-Curie National Research Institute of Oncology, Warsaw, 157 Poland.<sup>121</sup>Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway.<sup>122</sup>BESE Division, 158 KAUST, KSA, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia.<sup>123</sup>Department of Psychiatry, 159 University of Lausanne-University Hospital of Lausanne (UNIL-CHUV), Lausanne, Switzerland, <sup>124</sup>Department of 160 Psychiatry, University of Campania "Luigi Vanvitelli", Naples, Italy.<sup>125</sup>Center for Integrative Genomics, University of

161 Lausanne, Lausanne, Switzerland.<sup>126</sup>Department of Paediatric Laboratory Medicine, Division of Genome Diagnostics, The 162 Hospital for Sick Children, Toronto, Ontario, Canada.<sup>127</sup>Center for Psychiatry Research, Stockholm Health Care Services, 163 Stockholm City Council, Stockholm, Sweden.<sup>128</sup>Department of Psychiatry, Psychosomatics and Psychotherapy, University 164 of Würzburg, Würzburg, Germany.<sup>129</sup>Department of Psychiatry, University College Cork, Cork, Ireland.<sup>130</sup>Child and 165 Adolescent Regional Eating Disorder Service (CAREDS), Health Service Executive South, Cork, Ireland.<sup>131</sup>Institute of 166 Molecular and Cell Biology, University of Tartu, Tartu, Estonia.<sup>132</sup>Molecular Epidemiology Section, Department of 167 Biomedical Datasciences, Leiden University Medical Centre, Leiden, The Netherlands.<sup>133</sup>Department of Psychiatry, 168 Faculty of Medicine, University of Geneva, Geneva, Switzerland.<sup>134</sup>Department of Pediatrics, Gynaecology and Obstetrics, 169 University of Geneva, Geneva, Switzerland.<sup>135</sup>Department of Psychiatry and Behavioral Science, University of North 170 Dakota School of Medicine and Health Sciences, Fargo, North Dakota, USA.<sup>136</sup>National Center for PTSD, VA Boston 171 Healthcare System, Boston, Massachusetts, USA.<sup>137</sup>Department of Psychiatry, Boston University School of Medicine, 172 Boston, Massachusetts, USA.<sup>138</sup>Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University 173 of Salerno, Salerno, Italy.<sup>139</sup>Queensland Brain Institute, University of Queensland, Brisbane, Queensland, 174 Australia.<sup>140</sup>Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of 175 Florence, Florence, Italy.<sup>141</sup>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.<sup>142</sup>Population Health Department, 176 QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.<sup>143</sup>Center for Neurobehavioral Genetics, 177 Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, 178 USA.<sup>144</sup>Department of Psychiatry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The 179 Netherlands.<sup>145</sup>Kartini Clinic, Portland, Oregon, USA.<sup>146</sup>Center for Human Genome Research, Massachusetts General 180 Hospital, Boston, Massachusetts, USA.<sup>147</sup>INSERM U1124, Université de Paris, Paris, France.<sup>148</sup>Biostatistics and 181 Computational Biology Unit, University of Otago, Christchurch, New Zealand.<sup>149</sup>Department of Adolescent Psychiatry, 182 Helsinki University Hospital, Helsinki, Finland.<sup>150</sup>Institute of Clinical Medicine, University of Oslo, Oslo, 183 Norway.<sup>151</sup>Department of Health Science, University of Florence, Florence, Italy.<sup>152</sup>Department of Biometry, University of 184 Helsinki, Helsinki, Finland.<sup>153</sup>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General 185 Hospital and Harvard Medical School, Boston, Massachusetts, USA.<sup>154</sup>Stanley Center for Psychiatric Research, Broad 186 Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, 187 USA.<sup>155</sup>Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin, Berlin, Germany.<sup>156</sup>Department of 188 Psychiatry, Neurobiology, Pharmacology, and Biotechnologies, University of Pisa, Pisa, Italy.<sup>157</sup>Department of Psychiatry, 189 Poznan University of Medical Sciences, Poznan, Poland.<sup>158</sup>Department of Neurosciences, Padua Neuroscience Center, 190 University of Padova, Padova, Italy.<sup>159</sup>Institute of Medical Statistics, Computer and Data Sciences, Jena University 191 Hospital, Jena, Germany.<sup>160</sup>Department of Genetics and Genomic Biology, The Hospital for Sick Children, Toronto, 192 Ontario, Canada.<sup>161</sup>McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada.<sup>162</sup>Institute of Psychiatry, 193 Psychology and Neuroscience, Psychological Medicine, King's College London, London, UK.<sup>163</sup>J. Craig Venter Institute 194 (JCVI). La Jolla, California, USA.<sup>164</sup>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, 195 Austria.<sup>165</sup>First Faculty of Medicine, Department of Biology and Medical Genetics, Charles University, Prague, Czech

196 Republic.<sup>166</sup>Center for Eating Disorders Ursula, Rivierduinen, Leiden, The Netherlands, <sup>167</sup>Department of Psychiatry, 197 Leiden University Medical Centre, Leiden, The Netherlands.<sup>168</sup>Department of Child and Adolescent Psychiatry, Poznan 198 University of Medical Sciences, Poznan, Poland.<sup>169</sup>Donor Health and Genomics, National Institute for Health Research 199 Blood and Transplant Unit, Cambridge, UK.<sup>170</sup>Division of Cardiovascular Medicine, British Heart Foundation Centre of 200 Excellence, Cambridge, UK.<sup>171</sup>Department of Haematology, University of Cambridge, Cambridge, UK.<sup>172</sup>Center for 201 Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway.<sup>173</sup>Department of Clinical 202 Science, University of Bergen, Bergen, Norway.<sup>174</sup>Department of Psychiatry and Biobehavioral Science, Semel Institute 203 for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, USA.<sup>175</sup>David 204 Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.<sup>176</sup>Department of Cell 205 Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.<sup>177</sup>Department of 206 Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland.<sup>178</sup>Eating Disorders Research and 207 Treatment Center, Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische Universität Dresden, 208 Dresden, Germany.<sup>179</sup>Department of Psychiatry, University of Perugia, Perugia, Italy.<sup>180</sup>Brain Sciences Department, 209 Stremble Ventures, Limassol, Cyprus.<sup>181</sup>Adolescent Health Unit, Second Department of Pediatrics, "P. & A. Kyriakou" 210 Children's Hospital, University of Athens, Athens, Greece.<sup>182</sup>Pediatric Intensive Care Unit, "P. & A. Kyriakou" Children's 211 Hospital, University of Athens, Athens, Greece.<sup>183</sup>Faculty of Social and Behavioral Sciences, Utrecht University, Utrecht, 212 The Netherlands.<sup>184</sup>School of Psychology, Flinders University, Adelaide, South Australia, Australia.<sup>185</sup>School of 213 Psychology, Curtin University, Perth, Western Australia, Australia.<sup>186</sup>School of Paediatrics and Child Health, University of 214 Western Australia, Perth, Western Australia, Australia.<sup>187</sup>Department of Clinical Medicine, University of Copenhagen, 215 Copenhagen, Denmark.<sup>188</sup>Helmholtz Centre Munich – German Research Center for Environmental Health, Munich, 216 Germany.<sup>189</sup>Centre for Mental Health, University Health Network, Toronto, Ontario, Canada.<sup>190</sup>Program for Eating 217 Disorders, University Health Network, Toronto, Ontario, Canada.<sup>191</sup>TUM School of Medicine, Technical University of 218 Munich and Klinikum Rechts der Isar, Munich, Germany.<sup>192</sup>Department of Internal Medicine VI, Psychosomatic Medicine 219 and Psychotherapy, University Medical Hospital Tuebingen, Tuebingen, Germany.<sup>193</sup>Centre of Excellence for Eating 220 Disorders (KOMET), University Tuebingen, Tuebingen, Germany.